Peapack-Gladstone Financial Corp’s CRISPR Therapeutics CRSP Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$332K	Buy	6,988 +15	+0.2%	+$791	﹤0.01%	564
2025 Q4	$366K	Hold	6,973	–	–	﹤0.01%	548
2025 Q3	$452K	Hold	6,973	–	–	0.01%	521
2025 Q2	$339K	Buy	6,973 +200	+3%	+$7.74K	﹤0.01%	536
2025 Q1	$230K	Hold	6,773	–	–	﹤0.01%	615
2024 Q4	$266K	Hold	6,773	–	–	﹤0.01%	590
2024 Q3	$318K	Buy	6,773 +130	+2%	+$6.6K	﹤0.01%	561
2024 Q2	$359K	Hold	6,643	–	–	0.01%	535
2024 Q1	$453K	Buy	6,643 +2,053	+45%	+$147K	0.01%	499
2023 Q4	$288K	Hold	4,590	–	–	﹤0.01%	577
2023 Q3	$208K	Hold	4,590	–	–	﹤0.01%	630
2023 Q2	$258K	Buy	+4,590	New	+$260K	﹤0.01%	595

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Peapack-Gladstone Financial Corp's CRSP Position: Q1 2026 in Review

Peapack-Gladstone Financial Corp increased its CRISPR Therapeutics (CRSP) stake by 0.22% in Q1 2026, buying an estimated $791 and bringing the position to 6,988 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #564.

Peapack-Gladstone Financial Corp first reported a position in CRSP in Q2 2023 and has held it in 12 quarters since. The position peaked at $453K in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Peapack-Gladstone Financial Corp held 6,988 shares of CRISPR Therapeutics worth $332K as of Q1 2026.
Peapack-Gladstone Financial Corp bought 15 CRISPR Therapeutics shares in Q1 2026, an estimated $791.
CRISPR Therapeutics made up ﹤0.01% of Peapack-Gladstone Financial Corp's portfolio in Q1 2026, its #564 holding.
Peapack-Gladstone Financial Corp first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 12 quarters since.
Peapack-Gladstone Financial Corp's CRISPR Therapeutics position peaked at $453K in Q1 2024.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2026, filed 15 May 2026.